Free Trial
→ How to claim a stake in SpaceX before the June 12 IPO (From Brownstone Research) (Ad)tc pixel
NASDAQ:NYXH

Nyxoah 2/14/2026 Earnings Report

Nyxoah logo
$2.89 +0.07 (+2.62%)
As of 10:21 AM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Nyxoah EPS Results

Actual EPS
-$0.69
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Nyxoah Revenue Results

Actual Revenue
$6.62 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nyxoah Announcement Details

Quarter
Date
2/14/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Nyxoah's Q2 2026 earnings is estimated for Wednesday, August 5, 2026, based on past reporting schedules, with a conference call scheduled at 3:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Nyxoah Earnings Headlines

Information on the total number of voting rights and shares
May 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/20/3298901/0/en/information-on-the-total-number-of-voting-rights-and-shares.html
Nyxoah Welcomes the Flemish Investors Federation (VFB) at LégiaPark following Q1 2026 Results and U.S. Commercial Momentum
May 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/20/3298846/0/en/nyxoah-welcomes-the-flemish-investors-federation-vfb-at-l%c3%a9giapark-following-q1-2026-results-and-u-s-commercial-momentum.html
Trump Issues Emergency Order That Supports Elon Musk's Next Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.tc pixel
May 28 at 1:00 AM  |  Altimetry (Ad)
Nyxoah SA (NYXH) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
May 13, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4904312-nyxoah-sa-nyxh-presents-at-bank-of-america-global-healthcare-conference-2026-prepared-remarks
Nyxoah SA (NYXH) Q1 2026 Earnings Call Transcript
May 12, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4903539-nyxoah-sa-nyxh-q1-2026-earnings-call-transcript
Nyxoah Calls June 10 Shareholder Meetings and Files Q1 2026 Results
May 12, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/nyxoah-calls-june-10-shareholder-meetings-and-files-q1-2026-results?utm_source=marketbeat.com&utm_medium=referral
See More Nyxoah Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nyxoah? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nyxoah and other key companies, straight to your email.

About Nyxoah

Nyxoah (NASDAQ:NYXH), headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient. Prior to bedtime, users apply the activation patch, which wirelessly powers the implant and delivers timed electrical pulses to the tongue muscles. Following a CE mark in 2019, Nyxoah initiated commercial launches across Europe and select international markets. The company is actively pursuing additional regulatory clearances, including a premarket application with the U.S. Food and Drug Administration, and is conducting ongoing clinical studies to expand the system’s indications and validate long-term safety and efficacy.

Building on its flagship product, Nyxoah continues to invest in research and development aimed at next-generation neuromodulation platforms for various sleep-related disorders. The company maintains a global footprint with commercial operations in Europe and a subsidiary in the United States, and collaborates with leading sleep centers to drive physician adoption and patient access. Nyxoah’s management team combines expertise in medical devices, sleep medicine, and implantable technologies to advance its mission of improving outcomes for patients suffering from obstructive sleep apnea.

View Nyxoah Profile
Earnings Tools